{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:37Z","timestamp":1792831057409,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["836041010"],"award-info":[{"award-number":["836041010"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although ursodeoxycholic acid (UDCA) is commonly prescribed for primary sclerosing cholangitis (PSC), a beneficial long-term effect on solid clinical endpoints has not yet been established. This study evaluated the efficacy of UDCA on long-term transplant-free survival in a longitudinal population-based cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retro\/prospective study between January 2008 and August 2020, using data from the Dutch population-based EpiPSC2 cohort. Medication use was collected through medical chart review, periodic questionnaires, and the national pharmacy prescription database. The effect of UDCA use was assessed as time-dependent variable using a Cox proportional hazards model. Sex, age at diagnosis, PSC type, IBD status, transplant center inclusion, and PSC diagnosis year were considered as covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Medication data were available for 739 cases. Individuals with uncertain use of UDCA were excluded, resulting in a study population of 527. No discernable effect of UDCA use was observed on the endpoints liver transplantation (LT)\/all-cause mortality [adjusted HR 1.13 (95%CI 0.76\u20131.67)] nor LT\/PSC-related death\/occurrence of hepatobiliary malignancy [adjusted HR 1.07 (95%CI 0.71\u20131.60)]. The HR of UDCA use was numerically reduced for hepatobiliary malignancy [0.68 (95%CI 0.34\u20131.37)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study failed to demonstrate that UDCA use impacts long-term outcomes in patients with PSC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00535-026-02449-7","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:04:24Z","timestamp":1781539464000},"page":"1643-1652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based study"],"prefix":"10.1007","volume":"61","author":[{"given":"Bregje","family":"Mol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"van Munster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinse","family":"Weersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akin","family":"Inderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Boonstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"van Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsemieke","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Spanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Vrij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Verlaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"van Duijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn","family":"Ponsioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Dijkgraaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-0453","authenticated-orcid":false,"given":"Cyriel","family":"Ponsioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EpiPSC2 study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"2449_CR1","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","volume":"58","author":"K Boonstra","year":"2013","unstructured":"Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045\u201355.","journal-title":"Hepatology"},{"issue":"1","key":"2449_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/00365521.2019.1707277","volume":"55","author":"N Barner-Rasmussen","year":"2020","unstructured":"Barner-Rasmussen N, Pukkala E, Jussila A, et al. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scand J Gastroenterol. 2020;55(1):74\u201381. https:\/\/doi.org\/10.1080\/00365521.2019.1707277.","journal-title":"Scand J Gastroenterol"},{"key":"2449_CR3","volume":"3","author":"F Saffioti","year":"2017","unstructured":"Saffioti F, Gurusamy KS, Hawkins N, et al. Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:Cd011343.","journal-title":"Cochrane Database Syst Rev"},{"key":"2449_CR4","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","volume":"62","author":"U Beuers","year":"2015","unstructured":"Beuers U, Trauner M, Jansen P, et al. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015;62:S25-37.","journal-title":"J Hepatol"},{"key":"2449_CR5","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/hep.23810","volume":"52","author":"U Beuers","year":"2010","unstructured":"Beuers U, Hohenester S, de Buy Wenniger LJ, et al. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology (Baltim, MD). 2010;52:1489\u201396.","journal-title":"Hepatology (Baltim, MD)"},{"key":"2449_CR6","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jhep.2021.03.029","volume":"75","author":"M Reich","year":"2021","unstructured":"Reich M, Spomer L, Klindt C, et al. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. J Hepatol. 2021;75:634\u201346.","journal-title":"J Hepatol"},{"key":"2449_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24691","volume":"55","author":"S Hohenester","year":"2012","unstructured":"Hohenester S, Wenniger LM, Paulusma CC, et al. A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology (Baltim, MD). 2012;55:173\u201383.","journal-title":"Hepatology (Baltim, MD)"},{"key":"2449_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","volume":"11","author":"L Lindstr\u00f6m","year":"2013","unstructured":"Lindstr\u00f6m L, Hultcrantz R, Boberg KM, et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013;11:841\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2449_CR9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","volume":"77","author":"O Chazouilleres","year":"2022","unstructured":"Chazouilleres O, Beuers U, Bergquist A, Karlsen TH, Levy C, Samyn M, et al. EASL clinical practice guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761\u2013806.","journal-title":"J Hepatol"},{"key":"2449_CR10","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","volume":"68","author":"MH Chapman","year":"2019","unstructured":"Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68:1356\u201378.","journal-title":"Gut"},{"key":"2449_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","volume":"77","author":"CL Bowlus","year":"2023","unstructured":"Bowlus CL, Arriv\u00e9 L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology (Baltim, MD). 2023;77:659\u2013702.","journal-title":"Hepatology (Baltim, MD)"},{"key":"2449_CR12","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/liv.15471","volume":"43","author":"KN van Munster","year":"2023","unstructured":"van Munster KN, Mol B, Goet JC, et al. Disease burden in primary sclerosing cholangitis in the Netherlands: a long-term follow-up study. Liver Int. 2023;43:639\u201348.","journal-title":"Liver Int"},{"key":"2449_CR13","unstructured":"Castor EDC. Castor Electronic Data Capture (2024). https:\/\/www.castoredc.com\/. Accessed 24 Jun 2024"},{"key":"2449_CR14","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1214\/aos\/1176345976","volume":"10","author":"PK Andersen","year":"1982","unstructured":"Andersen PK, Gill RD. Cox\u2019s regression model for counting processes: a large sample study. Ann Stat. 1982;10:1100\u201320, 21.","journal-title":"Ann Stat"},{"key":"2449_CR15","volume-title":"RStudio: integrated development for R","author":"Team R","year":"2020","unstructured":"Team R. RStudio: integrated development for R. Boston, MA: RStudio, PBC; 2020."},{"key":"2449_CR16","volume-title":"IBM SPSS statistics for windows, version 28.0","author":"Corp I","year":"2021","unstructured":"Corp I. IBM SPSS statistics for windows, version 28.0. Armonk, NY: IBM Corp; 2021."},{"issue":"11","key":"2449_CR17","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s00535-022-01914-3","volume":"57","author":"T Arizumi","year":"2022","unstructured":"Arizumi T, Tazuma S, Isayama H, et al. Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis. J Gastroenterol. 2022;57(11):902\u201312.","journal-title":"J Gastroenterol"},{"key":"2449_CR18","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.23082","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Kowdley KV, Luketic VA, et al. High-dose Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808\u201314.","journal-title":"Hepatology"},{"key":"2449_CR19","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","volume":"129","author":"R Olsson","year":"2005","unstructured":"Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129:1464\u201372.","journal-title":"Gastroenterology"},{"key":"2449_CR20","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/hep.29882","volume":"68","author":"CY Ponsioen","year":"2018","unstructured":"Ponsioen CY, Lindor KD, Mehta R, et al. Design and endpoints for clinical trials in primary sclerosing cholangitis. Hepatology. 2018;68:1174\u201388.","journal-title":"Hepatology"},{"key":"2449_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1365-2036.2011.04822.x","volume":"34","author":"CK Triantos","year":"2011","unstructured":"Triantos CK, Koukias NM, Nikolopoulou VN, et al. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34:901\u201310.","journal-title":"Aliment Pharmacol Ther"},{"key":"2449_CR22","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.cgh.2018.11.002","volume":"17","author":"K Stokkeland","year":"2019","unstructured":"Stokkeland K, H\u00f6ijer J, Bottai M, et al. Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2019;17:1860-6.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2449_CR23","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1023\/A:1026686530785","volume":"44","author":"P Sauer","year":"1999","unstructured":"Sauer P, Benz C, Rudolph G, et al. Influence of cholestasis on absorption of ursodeoxycholic acid. Dig Dis Sci. 1999;44:817\u201322.","journal-title":"Dig Dis Sci"},{"key":"2449_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/hep.510260102","volume":"26","author":"A Benedetti","year":"1997","unstructured":"Benedetti A, Alvaro D, Bassotti C, et al. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. Hepatology. 1997;26:9\u201321.","journal-title":"Hepatology"},{"key":"2449_CR25","doi-asserted-by":"publisher","first-page":"G550","DOI":"10.1152\/ajpgi.00256.2016","volume":"312","author":"JBJ Ward","year":"2017","unstructured":"Ward JBJ, Lajczak NK, Kelly OB, et al. Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. Am J Physiol Gastrointest Liver Physiol. 2017;312:G550\u20138.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2449_CR26","first-page":"1739","volume":"25","author":"GE Chung","year":"2011","unstructured":"Chung GE, Yoon J-H, Lee J-H. Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth. Oncol Rep. 2011;25:1739\u201346.","journal-title":"Oncol Rep"},{"key":"2449_CR27","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/1751-2980.12191","volume":"15","author":"L Zhu","year":"2014","unstructured":"Zhu L, Shan LJ, Liu YJ, et al. Ursodeoxycholic acid induces apoptosis of hepatocellular carcinoma cells in vitro. J Dig Dis. 2014;15:684\u201393.","journal-title":"J Dig Dis"},{"key":"2449_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/CEJ.0b013e32834ef16f","volume":"21","author":"R Peir\u00f3-Jord\u00e1n","year":"2012","unstructured":"Peir\u00f3-Jord\u00e1n R, Krishna-Subramanian S, Hanski ML, et al. The chemopreventive agent ursodeoxycholic acid inhibits proliferation of colon carcinoma cells by suppressing c-Myc expression. Eur J Cancer Prev. 2012;21:413\u201322.","journal-title":"Eur J Cancer Prev"},{"key":"2449_CR29","first-page":"2585","volume":"16","author":"SH Kim","year":"2018","unstructured":"Kim SH, Chun HJ, Choi HS, et al. Ursodeoxycholic acid attenuates 5\u2011fluorouracil\u2011induced mucositis in a rat model. Oncol Lett. 2018;16:2585\u201390.","journal-title":"Oncol Lett"},{"key":"2449_CR30","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3892\/ol.2022.13568","volume":"24","author":"J Lee","year":"2022","unstructured":"Lee J, Hong EM, Kim JH, et al. Ursodeoxycholic acid inhibits epithelial\u2013mesenchymal transition, suppressing invasiveness of bile duct cancer cells: an in vitro study. Oncol Lett. 2022;24:448.","journal-title":"Oncol Lett"},{"key":"2449_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.7326\/0003-4819-134-2-200101160-00008","volume":"134","author":"BY Tung","year":"2001","unstructured":"Tung BY, Edmond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134:89\u201395.","journal-title":"Ann Intern Med"},{"key":"2449_CR32","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1158\/1940-6207.CAPR-09-0234","volume":"2","author":"PA Thompson","year":"2009","unstructured":"Thompson PA, Wertheim BC, Roe DJ, et al. Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. Cancer Prev Res (Phila). 2009;2:1023\u201330.","journal-title":"Cancer Prev Res (Phila)"},{"key":"2449_CR33","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.gastro.2013.06.052","volume":"145","author":"JE Eaton","year":"2013","unstructured":"Eaton JE, Talwalkar JA, Lazaridis KN, et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013;145:521\u201336.","journal-title":"Gastroenterology"},{"key":"2449_CR34","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1007\/s10620-013-2772-0","volume":"58","author":"JD Hansen","year":"2013","unstructured":"Hansen JD, Kumar S, Lo W-K, et al. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Dig Dis Sci. 2013;58:3079\u201387.","journal-title":"Dig Dis Sci"},{"key":"2449_CR35","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/MEG.0b013e3281108068","volume":"19","author":"G Rudolph","year":"2007","unstructured":"Rudolph G, Kloeters-Plachky P, Rost D, et al. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol. 2007;19:487\u201391.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02449-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02449-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02449-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:56:47Z","timestamp":1792828607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02449-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2449"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02449-7","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CYP reports research grants from Gilead, Perspectum, NGM, Dr. Falk,\u00a0and Takeda, and consultancy fees from Chemomab and Pliant. The other co-authors report no COIs.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}